dorsaVi (ASX:DVL) - CEO, Dr Andrew Ronchi
CEO, Dr Andrew Ronchi
Source: North Road Physiotherapy
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • dorsaVi’s (DVL) share price has skyrocketed 900 per cent after becoming a strategic partner of QBE Australia.
  • Under the new commercial collab, DVL will provide QBE customers with wearable devices to help reduce injury claims
  • dorsaVi’s on-body sensors will be used in real-time, monitoring and measuring movements, muscle activity and movement risks
  • As a result, Australia’s second-largest global insurer has pre-allocated $250,000 over an initial 12 month period to provide its customer with access to dorsaVi’s technology
  • Company shares are still up a considerable 462 per cent on the market today, trading for 7.3 cents each

dorsaVi’s (DVL) share price has skyrocketed 900 per cent after becoming a strategic partner of QBE Australia.

Under the new commercial collab, DVL will provide QBE customers with wearable devices to help reduce injury claims.

As a result, Australia’s second-largest global insurer has pre-allocated $250,000 over an initial 12 month period to provide its customer with access to dorsaVi’s technology.

QBE Australia’s General Manager for People Risk, Rob Kosova, said over the past two years, the company has been looking at ways to reduce the risk of injury at work.

“New technologies offer great promise for taking a proactive role in making workplaces safer and we’re excited to be working with dorsaVi’s technology to achieve this,” he said.

“The consequences of workplace injuries can be significant and sometimes, sadly, long-lasting. SafeWork Australia puts the total cost of workplace injury and disease at around four per cent of gross domestic product (GDP) over one-third of these are due to body stressing or manual handling,” he added.

Via the wearable tech, dorsaVi’s on-body sensors will be used in real-time and will monitor and measure movements, muscle activity and movement risk.

dorsaVi CEO Dr Andrew Ronchi is excited to partner with QBE.

“One of the goals for insurers is to be able to pro-actively manage risk and have remote visibility on where their potential risks are, allowing insurers and corporate groups to mitigate these risks and prove solutions before they are implemented,” he said.

“We look forward to adding value to the QBE Australia business and to their clients’ businesses,” he added.

Company shares are still up a considerable 462 per cent on the market today, trading for 7.3 cents each at 12:57 pm AEST.

DVL by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…